 | | Vol. 10.09 – 1 April, 2024 |
| |
|
|
| Scientists proposed that the β-mangostin-mediated melanin degradation mechanism was melanophagy, selective autophagy of melanosomes, and that autophagy receptor optineurin (OPTN) and an E3-ligase RCHY1 were required for this process.
[Proceedings Of The National Academy Of Sciences Of The United States Of America] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| | DERMAL STEM CELLS & TISSUE REGENERATION |
|
|
|
| Investigators demonstrated a vesicular-trafficking-mediated interplay between matriptase and epidermal growth factor (EGF) signaling in skin and breast cancer promotion. EGF induced matriptase to undergo endocytosis together with the EGF receptor, followed by acid-induced activation in endosomes.
[Cell Reports] |
|
|
|
| To determine direct effects on fibrotic fibroblasts, human dermal fibroblasts were treated with pro-fibrotic transforming growth factor-β1, followed by ketotifen or control treatments.
[Scientific Reports] |
|
|
|
| Scientists demonstrated a daytime radiative cooling dressing based on a polyamide 6/silk fibroin bilayer that reduced the thermal load for skin wounds under sunlight illumination.
[Nature Chemical Engineering] |
| |
|
|
| The authors performed a genome-wide characterization of ZEB1 transcriptional targets, by combining ChIP-sequencing and RNA-sequencing, upon phenotype switching in melanoma models.
[Oncogene] |
|
|
|
| Researchers investigated whether dual-specificity tyrosine-phosphorylation-regulated kinase (DYRK3) interacted with p62, and how this affected melanoma progression, particularly in melanoma cell lines.
[Journal Of Biological Chemistry] |
|
|
|
|
| The authors discuss the current understanding of the different phases of wound healing, from clot formation through re-epithelialization, angiogenesis and subsequent scar deposition.
[Nature Reviews Molecular Cell Biology] |
|
|
|
| Scientists summarize the research progress of isoflavones in melanoma, including anti-melanoma roles and mechanisms of isoflavones via inhibition of tyrosinase activity, melanogenesis, melanoma cell growth, invasion of melanoma cells, and induction of apoptosis in melanoma cells.
[Heliyon] |
|
|
|
|
| Incyte and China Medical System Holdings Limited (CMS) announced a collaboration and license agreement for the development of povorcitinib, a selective oral JAK1 inhibitor. CMS will receive a license to manufacture povorcitinib in dermatologic diseases, including vitiligo and hidradenitis suppurativa.
[Incyte Corporation] |
|
|
|
|
|
|
|
| | Karolinska Institute – Solna, Sweden |
|
|
|
| | abbvie – Irvine, California, United States |
|
|
|
| | University of Texas Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
| | Office of Women’s Health Grant Program – Jefferson, Arkansas, United States |
|
|
|
| | UC Davis – Davis, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
